cyrilzakka/clinical-trials huggingface dataset:
Tenting Screws in Combination With Platelet Concentrate for Vertical Alveolar Ridge Augmentation

Alveolar bone resorption often occurs after tooth extraction. At present, guided bone regeneration technique is widely used in clinic since it leads to less trauma and less complications. Tenting screw technology, basic on the classical GBR, implants screws into the surgical area to prevent the barrier membrane from collapsing. Moreover, advanced platelet rich fibrin and injectable platelet-rich fibrin are used to provide the osteogenic function. The investigators intend to increase vertical alveolar bone augmentation by combining tenting screws and A-PRF, I-PRF.

Alveolar bone resorption often occurs after tooth extraction. At present, guided bone regeneration technique is widely used in clinic since it leads to less trauma and less complications. Tenting screw technology, basic on the classical GBR, implants screws into the surgical area to prevent the barrier membrane from collapsing. Moreover, advanced platelet rich fibrin and injectable platelet-rich fibrin are used to provide the osteogenic function. The investigators intend to increase vertical alveolar bone augmentation by combining tenting screws and A-PRF, I-PRF.

Eligibility Criteria:
Inclusion Criteria:

1. 18-80 years old;
2. single tooth in the maxillary posterior area cannot be retained (third degree loosening / alveolar bone resorption to the periapical area), implantation is needed after extraction, and CBCT shows vertical bone defect ≥ 3mm;
3. 4 weeks after extraction or missing teeth within 3-5 weeks;
4. adjacent teeth exist and loosening is less than Ⅰ degree;
5. periodontal disease in inactive stage, whole mouth bleeding index (FMBS) is less than 20%;
6. thick gingival biological type.
7. CBCT shows that the bone of the edentulous site meets the requirements of tent screw implantation (bone height ≥ 3mm and bone mineral density is sufficient);
8. the patients and their families have informed consent and signed the informed consent form.

Exclusion Criteria:

1. pregnant and lactating women;
2. smoking (\> 10 cigarettes per day) and alcoholism;
3. taking anticoagulants within 3 months before operation;
4. suffering from autoimmune diseases, diabetes, liver disease, blood system diseases and infectious diseases;
5. patients taking any drugs that affect platelet function or whose platelet count is less than 200000/mm3 3 months before blood collection;
6. patients who have been treated with bisphosphate / steroids for a long time;
7. have received alveolar ridge bone augmentation surgery;
8. previous history of radiotherapy in the head and neck;
9. acute inflammation in edentulous sites;
10. inability to maintain good oral hygiene or follow-up visits as required.
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

The aim of this study is to test whether lymphatic surgery provides better QoL (assessed with the Lymph-ICF-UL, (Lymphedema Functioning Disability and health questionnaire for upper limb lymphedema)) 15 months after randomization (and therefore about one year after surgery) compared to conservative treatment only for patients with chronic lymphedema (LE)

To date, conservative complex physical decongestion therapy (CDT) is the gold standard for BCRL (breast cancer related lymphedema) and includes manual lymphatic drainage, local compression with bandages and garments, physical exercises and meticulous skin care. It is, however, too often ineffective to prevent stage progression in curing BCRL and purely symptomatic. Lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT) are two surgical techniques that, in contrast to CDT, are able to actually address the underlying causes and eventually restore the lymphatic drainage. LVA achieves this by creating numerous bypasses between lymphatic vessels and venules allowing the drainage of excessive fluid within the subcutaneous tissues into the venous system, while VLNT usually brings functioning lymph nodes to an area devoid of lymph nodes or with dysfunctional lymph nodes, thus enabling the spontaneous development of new lymphatic pathways. Both techniques have shown very promising results with low complication rates and improved Quality of Life (QoL) for the patients. However, no multicentric randomized controlled trial (RCT) has yet prospectively evaluated the superiority of these surgical techniques over CDT alone, limiting patient's access to most effective treatment available. Requests for cost reimbursement must still be submitted to insurance companies in most countries and are often rejected, thus delaying surgical treatment and resulting in prolonged suffering of affected patients. This is untenable seeing as affected patients suffer from a heavy physical, psychological and financial burden. This pragmatic, randomized, multicenter trial aims to establish a solid scientific basis assessing the superiority of surgical treatment over CDT alone.

Eligibility Criteria:
Inclusion Criteria:

* Written informed consent.
* Patients ≥ 18 years of age.
* Former diagnosis of breast cancer.
* Clinical diagnosis of chronic Breast Cancer-Related Lymphedema (BCRL) (persisting for more than 3 months) classified as ≥ Stage 1, according to ISL.
* Minimum of 3 months Conservative Complex Physical Decongestion Therapy.
* Ability to complete the QoL questionnaires.
* Willingness to undergo surgery.

Exclusion Criteria:

* No indication for lymphatic surgery according to clinical judgment of the treating surgeon (individual reasons will be specifically documented).
* Primary congenital Lymphedema or non-BCRL.
* Previous surgical BCRL treatment on the side intended for intervention.
A Study of a Telemedicine Program for Older Adults With Cancer

The purpose of this study is to find out if a telemedicine program for older adults in cancer treatment is a practical way to understand and meet these participants' unique needs. Telemedicine is the use of secure video technology on a desktop computer, laptop, smartphone, or tablet to provide and receive healthcare from a distance. The telemedicine program used in this study is called a tele-geriatric oncology program. It involves the participant and a study nurse meeting by videoconferencing during 2-6 telemedicine visits. As part of the program, the participant and the study nurse will discuss the participant's symptoms and aging-related needs.


Eligibility Criteria:
Inclusion Criteria:

* Age 70 or older
* Gastrointestinal or gynecological cancer.
* Receiving or about to receive medical cancer treatment (e.g., chemotherapy, immunotherapy, targeted therapy, biological agents)

Exclusion Criteria:

* Inability of the patient or caregiver to read or comprehend English
* No internet connection at home
* No electronic device with videoconferencing capability
Beyond Ageing Project: A Study for the Prevention of Depression

The purpose of this study is to determine whether folate and vitamin B12, physical activity and mental health literacy can prevent depression, and folate and vitamin B12 and physical activity can prevent cognitive impairment in older people. Also the study aims to assess the benefits for older people in improving their knowledge about mental health in relation to depression.

While preventive efforts for depression have tended to focus on adolescent and young adult populations, other stages of the lifespan also provide opportunities for prevention. With older people, there are certain risk and aetiological factors, which become more prominent and require preventive action at that point in the lifespan. The aim of this study is to determine the efficacy of various interventions in preventing depression and cognitive decline among older people who are at high risk of developing major depression because they are currently suffering from depressive symptoms.

The study has three interventions; i) folate and vitamin B12, ii) physical activity; and iii) mental health literacy. Participants will be randomly allocated to receive each combination of the interventions (folate and vitamin B12 or placebo, physical activity intervention programme or physical activity no-intervention control, mental health literacy intervention \[containing written modules with information about depression that is relevant to older people\] or mental health literacy no-intervention control group). Participants will receive these interventions over a two-year period with regular assessments across that time period.

Eligibility Criteria:
Inclusion Criteria:

* Aged 65-74 years with some depressive symptoms, assessed using the Kessler 10 Psychological Distress Scale \[K10\] (Andrews \& Slade, 2001)

Exclusion Criteria:

Any of the following:

* Those currently taking medication or receiving psychological treatment for depression
* A report of a medical diagnosis of bipolar disorder/mania
* History of epilepsy
* Diagnosed with cancer and/or on antifolate therapy
* Have a diagnosis of dementia or Alzheimer's disease
* Are currently taking vitamin supplements containing folate, B2, B6 or B12 at a dose exceeding 25% of the recommended daily intake.
* Medical contradictions to exercise (e.g., significant orthopaedic problems or cardiovascular disease that would prevent regular aerobic exercise)
* Ongoing participation in regular aerobic exercise.
A Subjective Observational Study of Patients Using Medicated Footbath/Footwash Treatment in Podiatry Care

The purpose of this study is to evaluate the level of relief perceived by patients using medicated footbath/footwash with or without an oral medication for the treatment of podiatry issues.

Footwash/Footbath for treatment of; Toenail fungus Ingrown toenails Cellulitis Athletes' foot Pitted Keratolysis Diabetic ulcers Open infected sores Abscesses Joint infections Wound care

Eligibility Criteria:
Inclusion Criteria:

Participants must be diagnosed with an ICD10 code indicative of Toenail Fungus, Ingrown Toenail, Cellulitis, Athletes Foot, Pitted Keratolysis, Diabetic Ulcers, Open infected sores, Abscesses, and Joint infections

* Participants must be starting a new regimen of a medicated footwash/foothbath
* Participants must be expecting to receive therapy for at least 12 weeks
* Participants must be between 18 and 64 years of age
* Participants must be able to provide sound verbal informed consent

Exclusion Criteria:

-

Participants must not be a beneficiary of government funded healthcare program (i.e. Medicare, Medicaid, etc.)

• Participants must not have a diagnosis of cancer within the past 5 years
Radiofrequency Ablation of Tumors

Background: This prospective study was designed to be the first to evaluate the toxicity of radiofrequency ablation (RFA) in patients with recurrent pediatric solid tumors.

Methods: From 2003 through 2006, we conducted a phase I, IRB-approved study of RFA for recurrent solid tumors. A multidisciplinary cancer management team selected appropriate candidates for the study. Imaging-guided RFA was performed percutaneously. Response was assessed at 3 months. Repeat RFA was performed for some incompletely ablated or new lesions.


Eligibility Criteria:
Inclusion Criteria:

General

* Any age
* Previously diagnosed malignancy (including aggressive fibromatosis) originally acquired during childhood (\<21 years-of-age)
* Patients who have undergone previous RFA may be enrolled again (different disease site) or receive subsequent ablation (same disease site) as long as the eligibility criteria are met at the time of re-enrollment, or a second ablation on study.
* The subject is medically appropriate for the study as determined by a consensus of professionals at multidisciplinary tumor conference prior to enrollment. This discussion will be documented in the chart of the potential subject to be recruited for this study.
* Histopathological material is available prior to the RF ablation except in patients with obvious tumor recurrence.
* No Pacemakers or Automatic Implantable Cardioverter/Defibrillators (AICDs)
* No tissue burns anticipated from implanted metal
* Normal renal function (Creatinine \< 2mg/dL)
* Absolute neutrophil count (ANC) \> 1000/cu.mm.
* No uncorrectable coagulopathy (INR\>1.5, PTT and PT \> 1.5 x the upper limit of normal)
* No uncorrectable thrombocytopenia (platelet count \< 50,000/mm3)
* Life expectancy over 30 days
* RF ablation targets in the liver, lung or musculoskeletal system that meet the following criteria:

Hepatic lesions

* Intrahepatic metastases not amenable to other therapy
* Primary hepatic tumor if RF ablation of a portion of the tumor can lead to primary tumor resection rather than hepatic transplantation
* Single primary or multiple tumors in the liver
* At least one over 0.5 cm in diameter
* Edge of lesion not contiguous with main hepatic or common biliary duct.

Musculoskeletal lesions

* Local or regional recurrence of primary bone or soft tissue tumor not amenable to resection or radiotherapy
* Osseous, soft tissue or lymph node metastases not amenable to resection or radiotherapy.
* Head, neck, spine, extremity, chest wall, flank, abdominal wall, or pelvic bone or girdle lesions are treatable under this protocol
* RFA target \< 50% of axial area in weight bearing bone unless reinforced with internal fixation (bone cement infusion) or in non-ambulatory patient.

Lung lesions

* No supplemental oxygenation is required.
* Metastatic solid tumor that has recurred or progressed after primary thoracotomy or thoracoscopic removal that is not amenable to radiotherapy, surgery or chemotherapy
* In the investigator's opinion, no supplemental oxygen will likely be required at rest for more than 30 days after RF ablation.
* Tumor burden \< 20% of lung volume
Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)

This study will evaluate the ability of oral montelukast/loratadine to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine alone, montelukast alone and placebo.


Eligibility Criteria:
Inclusion Criteria:

* Patient has a documented history of seasonal allergic rhinitis symptoms that flare up during the study season
* Patient is a nonsmoker
* Patient is in good general health

Exclusion Criteria:

* Patient is hospitalized
* Patient is a woman who is less than 8 weeks postpartum or is breast-feeding
* Patient intends to move or vacation away during the study
* Patient has had any major surgery within 4 weeks of study start
* Patient is a current or past abuser of alcohol or illicit drugs
* Patient has been treated in an emergency room for asthma in the past month
* Patient had an upper respiratory infection with in 3 weeks prior to study start
* Patient has any active pulmonary disorder other than asthma
New Protocol in Unexplained Infertility

The new protocol ANTIUI provides good results regarding ovulation and pregnancy rates in patients with unexplained infertility

Patients with unexplained infertility has normal investigations regarding hormonal, structural data. Semen is normal but no pregnancy occurs.

Before trying ICSI, we could help these patients with ANTIUI

Eligibility Criteria:
Inclusion Criteria:

* Unexplained infertility
* Duration less than 5 years
* Good ovarian reserve AMH\> 1.1
* Normal patent tubes
* No previous trials of IUI with the same protocol

Exclusion Criteria:

* Age \> 35 years
* Duration of infertility\> 5 years
* Abnormal semen
* Hypoplastic tubes
* prior failed ICSI
Analysis of Medication Data With the ApoMining-Database

The primary objective of this study is to analyse medication data from the BioCog Study with the ApoMining-Database and to determine the positive and negative predictive value from the ApoMining-Database for prediction of postoperative delirium (POD).

From 2014-2017 the BioCog Study (ClinicalTrials.gov Identifier: NCT02265263) collected data from 439 perioperative elderly patients in Campus Virchow - Klinikum, Universitätsmedizin Berlin. According to the study protocol, a delirium assessment was performed each day after operation until the 7th postoperative day. At this time, it is known which patients developed postoperative delirium (POD) and which did not. Additionally, from each patient data on long-term medication before operation and applied medication during operation and in the recovery room were collected. In this study, the investiagtors analyse the long-term medication and the perioperative medication from BioCog-Study patients with the ApoMining-Database (http://www.apothesen.de/index.php?id=878; ApoThesenGmbH; Bad Münstereifel; Germany). The ApoMining-Database is a medication database, which analyse tolerability and risks of medications for the elderly. The database generates a hit once a medication reveal a risk for delirium. Additionally, the database can calculate the anticholinergic burden of the medication according to the prescribing information. Whereas the investigators already know, which patient developed a POD, they will determine positive and negative predictive value from the ApoMining-Database for prediction of postoperative delirium.

Eligibility Criteria:
Inclusion Criteria:

* From BioCog study (NCT02265263)

Exclusion Criteria:

* From BioCog study (NCT02265263)

Additionally for this analysis:

Inclusion criteria:

• Enrollment at Campus Virchow - Klinikum, Charité - Universitätsmedizin Berlin

Exclusion criteria:

* No delirium assessment
* No long-term medication before operation
Young Adult EC Use and Respiratory Outcomes

E-cigarette (EC) use continues to increase among youth, and EC may be detrimental to youth respiratory health. Public health officials and the Food and Drug Administration (FDA) can now regulate ECs. The proposed study uses naturalistic assessments called ecological momentary assessment (EMA) to understand how ECs use may impact the respiratory health of youth and young adult users compared to never-using peers.

Using a prospective longitudinal design, 150 youth and young adults aged 18-25 years (100 exclusive-EC users; 50 never-users) will complete 5 sessions (baseline, 3-,6-, 9-, and 12-months). Sessions will include naturalistic measures such as measures of respiratory health, questionnaires, and nasal epithelial lining fluid (NELF) nasal samples. To assess acute changes in pulmonary functioning related to tobacco product use, participants will complete twice daily EMA and home-based spirometry for the 2 weeks following the Day 1 session and the 2 weeks prior to each follow-up zoom session. Never-users will participate in a brief 15-30-minute individual interview consisting of questions related to reasons for never-EC use and other protective factors that will be used to build future prevention messaging.

Eligibility Criteria:
Inclusion Criteria:

1. own a smartphone and willing to add study EMA and spirometry application to it.
2. a current exclusive-EC user (endorse ≥weekly use over the past 3 months) and report never trying OTPs
3. between the ages of 18-25 years old at the time of enrollment
4. read and speak English
5. willing to complete five, 2-week periods of daily EMA and home-based spirometry
6. never-users must indicate never trying any tobacco product to be eligible for enrollment

Exclusion Criteria:

1. self-reported diagnosis of lung disease including cystic fibrosis or chronic obstructive pulmonary disease; we will not exclude youth who have asthma, but will incorporate this as a covariate during analyses
2. unstable or significant psychiatric conditions (past and stable conditions will be allowed)
3. history of cardiac event or distress within the past 3 months
4. are currently pregnant, planning to become pregnant, or breastfeeding
5. are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability
Renal Acute MI Study

The purpose of this study is to determine if a sizable myocardial infarction (heart attack) results in negative changes to renal structure and function (i.e. has a negative impact on the kidneys).

To determine if the renal response to a myocardial infarction is a predictor of the patients future health.

Chronic heart and kidney disease are increasingly common in Western society. Both conditions are associated with frequent hospitalisation and increased mortality. Furthermore, there are mechanistic reasons why one condition may beget the other; the so-called "cardiorenal syndrome". The investigators therefore wish to determine if a sizable myocardial infarction (heart attack) results in negative changes to renal structure and function (i.e. has a negative impact on the kidneys). The investigators also wish to determine if the renal response to a myocardial infarction is a predictor of the patients future health. To do this the investigators will measure markers of kidney function at the time of the heart attach, at discharge, 1 month, 6 months and 12 months and correlate this with the patients clinical condition.

Eligibility Criteria:
Inclusion Criteria:

Age \> 18 years

Have provided written informed consent

Group 1:

* Non-Q wave MI patients
* normal cardiac and renal function
* No use of contrast
* eGFR \> 60ml/min

Group 2:

* Patients undergoing coronary angiography +/- PCI for stable CAD or non-Q wave MI
* normal cardiac and renal function
* eGFR \> 60ml/min

Group 3:

* Acute STEMI Full thickness infarct (STEMI)
* eGFR ≥ 60ml/min

Group 4:

* Acute STEMI Full thickness infarct (STEMI)
* eGFR \< 60ml/min

Exclusion Criteria:

* Unable or unwilling to comply with the study protocol
* Underlying medical condition which, in the opinion of the investigator, will effect the safely or efficacy of the study
Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent form (ICF) and able to comply with study.
* Age ≥18 years, gender unlimited.
* Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression) within one year of histological or cytological diagnosis.
* Estimated survival \>12 weeks, as determined by the investigator.
* The United States Eastern Cancer Consortium (ECOG) physical status score 0-1.
* Has adequate organ function.
* At least 1 measurable tumor lesion according to RECISTv1.1 criteria.

Exclusion Criteria:

* Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
* Received prior therapies targeting HDAC.
* Chemotherapy was received within 21 days before the first administration of the study treatment, and anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy was received within 28 days before the first administration of the study treatment \[small molecule targeted drugs, Chinese medicines with anti-tumor indications, and local palliative radiotherapy were 14 times before the first administration of the study drug.
* Used strong CYP3A4 inhibitors or inducers within 7 days before the first use of the investigational drug.
* Major surgery or major injury \<=28 days before the first dose of study treatment,or anticipated major surgery during the study.
* Prior allogeneic bone marrow transplantation or other solid organ transplantation
* Active infection requiring systemic treatment.
* Current or past presence of other malignancies (other than adequately treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix), unless radical treatment has been performed and there is no evidence of recurrence and metastasis in the last 5 years.
* A person is known to be allergic to any active ingredient or excipient of the investigational drug.
* Pregnant or lactating women.
* patients with drug abuse or chronic alcohol abuse that may affect the evaluation of the test results.